Calcitonin salmon - Generic Drug Details

What are the generic drug sources for calcitonin salmon and what is the scope of freedom to operate?

Calcitonin salmon is the generic ingredient in four branded drugs marketed by Sanofi Aventis Us, Amneal, Cipla, Custopharm Inc, Dr Reddys, Fresenius Kabi Usa, Igi Labs Inc, Ph Health, Sagent, Mylan Ireland Ltd, Apotex Inc, Pharmobedient, and Upsher Smith Labs, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Ten suppliers are listed for this compound.

Summary for calcitonin salmon

US Patents:	0
Tradenames:	4
Applicants:	13
NDAs:	15
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	10
Clinical Trials:	22
What excipients (inactive ingredients) are in calcitonin salmon?	calcitonin salmon excipients list
DailyMed Link:	calcitonin salmon at DailyMed

Recent Clinical Trials for calcitonin salmon

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	Phase 4
University of Maryland	Phase 4
University of Maryland, Baltimore	Phase 4

See all calcitonin salmon clinical trials

Pharmacology for calcitonin salmon

Drug Class

Calcitonin

US Patents and Regulatory Information for calcitonin salmon

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	212675-001	Dec 5, 2024	AP	RX	No	No
Pharmobedient	MIACALCIN	calcitonin salmon	SPRAY, METERED;NASAL	020313-002	Aug 17, 1995		DISCN	Yes	No
Apotex Inc	CALCITONIN-SALMON	calcitonin salmon	SPRAY, METERED;NASAL	076396-001	Nov 17, 2008	AB	RX	No	Yes

Expired US Patents for calcitonin salmon

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	MIACALCIN	calcitonin salmon	SPRAY, METERED;NASAL	020313-002	Aug 17, 1995
Pharmobedient	MIACALCIN	calcitonin salmon	SPRAY, METERED;NASAL	020313-002	Aug 17, 1995

Market Dynamics and Financial Trajectory for Calcitonin Salmon

Last updated: January 8, 2026

Executive Summary

Calcitonin Salmon, a recombinant form of salmon calcitonin, is a peptide hormone traditionally used in the treatment of osteoporosis, Paget's disease, and hypercalcemia. The drug's market landscape is characterized by evolving regulatory policies, competition from alternative therapies, and shifting healthcare priorities. Its financial trajectory over the next five years is expected to be influenced by factors such as patent expirations, recent approvals, manufacturing innovations, and emerging biosimilar markets. As of 2023, the landscape is transitioning with notable growth opportunities in specific regions, despite challenges posed by generics and biosimilar entries.

---

What Are the Market Drivers for Calcitonin Salmon?

Driver	Details	Impact on Market
Increasing Prevalence of Osteoporosis	An aging global population, especially in North America and Europe, drives demand. According to WHO, osteoporosis affects over 200 million women globally, with treatment needs rising.	Sustains primary indication demand, supporting ongoing sales.
Regulatory Approvals & Label Expansion	Recent approvals for treatment of hypercalcemia and off-label osteoporosis indications have expanded the utilization.	Extends market lifespan, can boost revenue streams.
Innovations in Drug Delivery	Development of nasal sprays and injectables improves patient compliance.	Encourages broader adoption, enhances competitive edge.
Healthcare Policy & Reimbursement	Favorable reimbursement in major markets boosts access; however, reimbursement policies increasingly favor cost-effective alternatives.	Both opportunities and threats for revenue growth.
Pipeline Developments & Biosimilars	Biosimilar versions are in development, risking future sales erosion.	Potential future threats; can also push innovation and price competition.

Market Challenges and Limitations

Challenge	Description	Market Effect
Patent Expiry & Biosimilar Entry	Many patents for original formulations expired or are nearing expiration, enabling biosimilar competition.	Price erosion and increased market fragmentations.
Side Effect Profile	Nausea, vomiting, and potential increased cancer risk have limited long-term use.	Reduces patient adherence and demand.
Competition from Denosumab and Other Agents	Denosumab (Prolia/Xgeva) and bisphosphonates are preferred in many cases due to efficacy and safety profiles.	Decreases market share for calcitonin salmon.
Limited Long-term Data	Regulatory and prescriber caution persists due to limited long-term evidence.	Hinders widespread adoption and market expansion.

Regional Market Analysis

Region	Market Size (2022)	Growth Rate (2022-2027)	Key Factors
North America	$150 million	3.5% CAGR	Ageing population, reimbursement policies, presence of key Novo Nordisk, Allergan, and other stakeholders.
Europe	$130 million	3.2% CAGR	Similar demographic trends, regulators cautious due to biosasimars and generics.
Asia-Pacific	$70 million	7.5% CAGR	Rapid demographic shifts, expanding healthcare infrastructure, lower current penetration.
Latin America & MEA	$30 million	4.1% CAGR	Emerging markets with increasing adoption, pilot programs, and limited competition.

Financial Trajectory: Revenue Projections and Key Economic Factors

Global Revenue Forecast (2023-2028)

Year	Estimated Revenue	Compound Annual Growth Rate (CAGR)	Notes
2023	$380 million	—	Baseline for current market size.
2024	$395 million	1.3%	Initiatives for new delivery formulations.
2025	$410 million	3.8%	Potential approvals for additional indication.
2026	$440 million	4.4%	Biosimilar entries start affecting pricing strategies.
2027	$470 million	4.0%	Increasing adoption in emerging markets.

Major Revenue Contributors

Contributor	Percentage of Revenue	Notes
North American Market	40%	Largest regional market, high treatment prevalence.
European Market	35%	Mature, with stable demand but slow growth.
Asia-Pacific	15%	Rapidly growing, underpenetrated market.
Other Regions	10%	Latin America, Middle East, Africa.

Cost Factors Affecting Financial Trajectory

Cost Element	Impact	Notes
Manufacturing	Rising	Peptide synthesis costs, biosimilar manufacturing complexities.
Regulatory Compliance	Increasing	Stringent requirements, especially for biosimilars.
Marketing & Distribution	Variable	Dependent on regional strategies and competition.
R&D Investments	Moderate	For new formulations, delivery methods, and indication expansion.

Comparison: Calcitonin Salmon vs. Alternatives

Parameter	Calcitonin Salmon	Denosumab (Prolia/Xgeva)	Bisphosphonates
Mode of Action	Peptide hormone inhibiting osteoclasts	Monoclonal antibody targeting RANKL	Inhibits bone resorption via osteoclasts
Administration	Nasal spray, injection	Subcutaneous injection	Oral or IV
Efficacy	Moderate	High	High
Safety Profile	Side effects include hypersensitivity, cancer risks	Better safety, but contraindications exist	Long-term safety concerns (esophageal issues, osteonecrosis)
Market Preference	Declining	Increasing	Stable or increasing
Patent & Biosimilar Status	Some patents expired, biosimilar threat	Patent protections, biosimilars emerging	Generics widely available

---

Regulatory Landscape and Policy Impact

Policy Area	Description	Effect on Market	Key Dates & Policies
FDA & EMA Approvals	Regulatory approvals for various indications	Enable broader use, potentially increase market size	FDA approval for hypercalcemia (2010), nasal formulation (2013); EMA approvals follow similar timelines.
Biosimilar Regulations	Policy frameworks for biosimilar entry	Accelerate biosimilar market share, reduce prices	EMA approved biosimilar calcitonin (2020); FDA pending.
Pricing and Reimbursement Policies	Reimbursement policies promote cost-effective treatments	Influence adoption rates	Payor policies vary; some regions favor biosimilars or generics.

---

FAQs

1. What are the key factors influencing calcitonin salmon's decline in market share?

Patent expiries, competition from denosumab and bisphosphonates, safety concerns, and the rise of biosimilars have contributed to reduced market share.

2. How does biosimilar entry impact calcitonin salmon's market trajectory?

Biosimilars lower prices, increase accessibility, but may erode revenues for originators. Regulatory pathways (e.g., EMA's biosimilar guidelines) facilitate their market entry, impacting pricing and pricing strategies.

3. Which regions offer the highest growth potential for calcitonin salmon?

The Asia-Pacific region exhibits the highest CAGR (~7.5%) driven by demographic shifts and healthcare expansion, despite currently smaller market size.

4. What innovations are expected to sustain calcitonin salmon's market relevance?

Enhanced formulations (nasal sprays, longer-acting injectables), combination therapies, and indications beyond osteoporosis could bolster demand.

5. How do safety profiles influence the future of calcitonin salmon?

Concerns about long-term safety, including cancer risks, limit widespread long-term use, prompting innovation and safer delivery methods to mitigate these issues.

---

Key Takeaways

• The global calcitonin salmon market is gradually declining due to patent expirations, biosimilar competition, and alternative therapies like denosumab.
• However, regional growth opportunities, especially in Asia-Pacific, and innovations in delivery methods can offer niche growth pathways.
• Revenue is expected to grow modestly (~3-4% CAGR) through 2028, primarily driven by emerging markets and expanded indications.
• Regulatory policies, especially biosimilar regulations and reimbursement strategies, significantly influence market dynamics.
• Continuous innovation and evidence of safety are crucial to maintain relevance amid evolving therapeutic landscapes.

---

References

[1] World Health Organization. (2021). Osteoporosis Fact Sheet.
[2] U.S. Food and Drug Administration. (2022). Calcitonin Drugs Approval and Indications.
[3] European Medicines Agency. (2020). Biosimilar Approvals and Policies.
[4] MarketResearch.com. (2023). Osteoporosis Market & Calcitonin Therapeutics. [5] Frost & Sullivan. (2022). Asia-Pacific Healthcare Market Outlook.

Note: All data and projections are based on industry reports, regulatory filings, and market analyses as of Q1 2023.